Myeloid Leukemia News and Research

RSS
Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

Study could refine treatment recommendations for younger adult patients with acute leukemia

Study could refine treatment recommendations for younger adult patients with acute leukemia

Study reveals impact of TP53 gene mutations on MDS severity

Study reveals impact of TP53 gene mutations on MDS severity

Study sheds light on potential new treatment approach in AML patients

Study sheds light on potential new treatment approach in AML patients

Researchers identify specific target sites for DNA methylases

Researchers identify specific target sites for DNA methylases

New cancer vaccine shows promising signs in preclinical studies

New cancer vaccine shows promising signs in preclinical studies

Mapping immune landscape of hematological malignancies may help improve cancer therapies

Mapping immune landscape of hematological malignancies may help improve cancer therapies

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Researchers discover new and improved way to treat poor-prognosis blood cancer

Researchers discover new and improved way to treat poor-prognosis blood cancer

Researchers call for caution of using CAR-T immunotherapy against AML

Researchers call for caution of using CAR-T immunotherapy against AML

Two potent small molecules appear to suppress tumor growth in multiple cancers

Two potent small molecules appear to suppress tumor growth in multiple cancers

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

Researchers discover key gene essential for survival of leukemia stem cells

Researchers discover key gene essential for survival of leukemia stem cells

KinaRx receives SBIR grant to speed up clinical trials for AML and other diseases

KinaRx receives SBIR grant to speed up clinical trials for AML and other diseases

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.